FGF23 and chronic kidney disease: When the same deletion is introduced in mice models of CKD (5/6 nephrectomy and high-phosphate diet)—which present with elevated serum phosphate, PTH, and FGF-23—α-Klotho expression in the bone was significantly decreased and the pro-osteoblastic effect was no longer significant.